SCHEMBL1524924

SCHEMBL1524924

CC(C)[CH]C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ADH1C P00326 2/20 0.34
ADH1A P07327 2/20 0.34
ADH1B P00325 1/20 0.34
SHBG P04278 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9979246 1.00 ADH1C (0.34) ADH1CADH1AADH1BSHBG
SCHEMBL8852367 1.00 ADH1C (0.34) ADH1CADH1AADH1BSHBG
SCHEMBL9979303 1.00 ADH1C (0.34) ADH1CADH1AADH1BSHBG
SCHEMBL9978796 0.97
SCHEMBL9979108 0.91
SCHEMBL1221452 0.84
SCHEMBL22788473 0.78 ADH1B (0.32) ADH1CADH1AADH1B
SCHEMBL8075544 0.76 SHBG (0.32) ADH1CADH1AADH1BSHBG
SCHEMBL5919192 0.74 SHBG (0.41) ADH1CADH1AADH1BSHBG
SCHEMBL7126650 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0243940-A2 Phenyl- and cyclohexyl-isobutylpyrrolidine BASF Aktiengesellschaft (DE) 1987-11-04 EP claimed
WO-2021219495-A1 METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-11-04 WO disclosed
US-20210338626-A1 METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) 2021-11-04 US disclosed
EP-3215505-B1 PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE Bayer Pharma AG (DE) 2019-07-24 EP disclosed
CN-110036068-A Concentrate composition 巴塞尔聚烯烃意大利有限公司 2019-07-19 CN disclosed
CN-109180843-A The non-phthalic acid ester compound as electron donor for polyolefin catalyst 美国台塑公司 2019-01-11 CN disclosed
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-11-06 US disclosed
CN-105339085-B Non-phthalate compounds as electron donors for polyolefin catalysts 美国台塑公司 2018-06-26 CN disclosed
EP-3277670-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2018-02-07 EP disclosed
EP-3277672-A1 INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER Bristol-Myers Squibb Company (US) 2018-02-07 EP disclosed
US-20030092708-A1 Anticholesterol agents; cardiovascular disorders; antilipemic agents JAPAN TOBACCO, INC., A JAPAN CORPORATION 2003-05-15 US disclosed
EP-1297101-A2 LAUNDRY SYSTEM HAVING UNITIZED DOSING THE PROCTER & GAMBLE COMPANY (US) 2003-04-02 EP disclosed
EP-0978531-B1 Rubber composition CONTINENTAL AG (DE) 2003-02-19 EP disclosed
US-6426365-B1 Anticholesterol agents; Cholesterol ester transfer protein (CETP); including dalcetrapib, S-(2-(((1-(2-ethylbutyl)cyclohexyl)carbonyl)amino) phenyl) 2-methylpropanethioate JAPAN TOBACCO INC. (JP) 2002-07-30 US disclosed
WO-2001085888-A2 LAUNDRY SYSTEM HAVING UNITIZED DOSING THE PROCTER & GAMBLE COMPANY (US) 2001-11-15 WO disclosed
US-6207757-B1 VULCANIZABLE RUBBER CONTAINS, A RUBBER COMPONENT, A FILLER WITH NUCLEOPHILIC GROUP, AN ADDITIONAL FILLER, GEL PARTICLES COMPRISING RUBBER CONTAINING ELECTROPHILIC CENTERS, A NUCLEOPHIC GROUP CONTAINING SILANE COUPLER CONTINENTAL AKTIENGESELLSCHAFT (DE) 2001-03-27 US disclosed
EP-1020439-A1 CETP ACTIVITY INHIBITORS JAPAN TOBACCO INC. (JP) 2000-07-19 EP disclosed
CN-1252053-A Cetp activity inhibitors JAPAN TOBACCO INC (JP) 2000-05-03 CN disclosed
EP-0978531-A1 Rubber composition Continental Aktiengesellschaft (DE) 2000-02-09 EP disclosed
US-4593090-A Containing perhydrofuran or pyran ring structure GOGO KIMURA (JP) 1986-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210338626-A1 METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION ACE, ACE2, REN ADH1C 2220/4885ADH1A 2420/4885ADH1B 1573/4885
US-20030092708-A1 Anticholesterol agents; cardiovascular disorders; antilipemic agents CETP, CES1, PON1 ADH1C 778/4885ADH1A 707/4885ADH1B 788/4885
US-10118930-B2 Piperidinylpyrazolopyrimidinones and their use HAMP, SERPINC1, PRSS8 ADH1C 1025/4885ADH1A 673/4885ADH1B 1502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.